Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation

Hepatology

Volumn 62, Issue 3, 2015, Pages 702-714

  Anggakusuma, ^a   Romero Brey, Inés ^b   Berger, Carola ^b   Colpitts, Che C ^c   Boldanova, Tujana ^d   Engelmann, Michael ^a   Todt, Daniel ^a   Perin, Paula Monteiro ^a   Behrendt, Patrick ^a,e   Vondran, Florian W R ^e   Xu, Shuting ^a   Goffinet, Christine ^a   Schang, Luis M ^c   Heim, Markus H ^d   Bartenschlager, Ralf ^b   Pietschmann, Thomas ^a   Steinmann, Eike ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYCHOLESTEROL; CHOLESTEROL 25 HYDROXYLASE; INTERFERON; MESSENGER RNA; OXYGENASE; UNCLASSIFIED DRUG; CHOLESTEROL 25-HYDROXYLASE; STEROID MONOOXYGENASE;

ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; MACROPHAGE; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; RNA REPLICATION; TARGET CELL; TISSUE CULTURE; UPREGULATION; VIRION; VIRUS GENOME; VIRUS REPLICATION; CELL CULTURE; DNA REPLICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; LIVER CELL; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; SENSITIVITY AND SPECIFICITY; VIRUS ENTRY;

BIOPSY, NEEDLE; CELLS, CULTURED; DNA REPLICATION; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; INTERFERONS; SENSITIVITY AND SPECIFICITY; STEROID HYDROXYLASES; UP-REGULATION; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84940019411     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27913     Document Type: Article

References (56)

1. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26:15S-20S.
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61:S45-S57.
3. Manns MP, von Hahn T. Novel therapies for hepatitis C-one pill fits all? Nat Rev Drug Discov 2013;12:595-610.
4. Tse MT. All-oral HCV therapies near approval. Nat Rev Drug Discov 2013;12:409-411.
5. Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013;19:879-888.
6. Schoggins JW, Randall G. Lipids in innate antiviral defense. Cell Host Microbe 2013;14:379-385.
7. Ablasser A, Hornung V. DNA sensing unchained. Cell Res 2013;23:585-587.
8. Metz P, Reuter A, Bender S, Bartenschlager R. Interferon-stimulated genes and their role in controlling hepatitis C virus. J Hepatol 2012;59:1331-1341.
9. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011;472:481-485.
10. Zhao H, Lin W, Kumthip K, Cheng D, Fusco DN, Hofmann O, et al. A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. J Hepatol 2012;56:326-333.
11. Haller O, Staeheli P, Schwemmle M, Kochs G. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol 2015;23:154-163.
12. Helbig KJ, Eyre NS, Yip E, Narayana S, Li K, Fiches G, et al. The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. Hepatology 2011;54:1506-1517.
13. Wilkins C, Woodward J, Lau DT, Barnes A, Joyce M, McFarlane N, et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 2013;57:461-469.
14. Meyer K, Kwon YC, Liu S, Hagedorn CH, Ray RB, Ray R. Interferon-alpha inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection. Sci Rep 2015;5:9012.
15. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008;8:559-568.
16. Liu SY, Sanchez DJ, Aliyari R, Lu S, Cheng G. Systematic identification of type I and type II interferon-induced antiviral factors. Proc Natl Acad Sci USA 2012;109:4239-4244.
17. Bauman DR, Bitmansour AD, McDonald JG, Thompson BM, Liang G, Russell DW. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc Natl Acad Sci USA 2009;106:16764-16769.
18. Park K, Scott AL. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. J Leukoc Biol 2010;88:1081-1087.
19. Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 2013;38:92-105.
20. Blanc M, Hsieh WY, Robertson KA, Kropp KA, Forster T, Shui G, et al. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity 2013;38:106-118.
21. Lund EG, Kerr TA, Sakai J, Li WP, Russell DW. cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism. J Biol Chem 1998;273:34316-34327.
22. Haid S, Grethe C, Dill MT, Heim M, Kaderali L, Pietschmann T. Isolate-dependent use of claudins for cell entry by hepatitis C virus. Hepatology 2014;59:24-34.
23. Kleine M, Riemer M, Krech T, DeTemple D, Jager MD, Lehner F, et al. Explanted diseased livers-a possible source of metabolic competent primary human hepatocytes. PLoS One 2014;9:e101386.
24. Steinmann E, Whitfield T, Kallis S, Dwek RA, Zitzmann N, Pietschmann T, et al. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 2007;46:330-338.
25. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002;76:13001-13014.
26. Berger C, Romero-Brey I, Radujkovic D, Terreux R, Zayas M, Paul D, et al. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. Gastroenterology 2014;147:1094-1105.
27. Diczfalusy U. On the formation and possible biological role of 25-hydroxycholesterol. Biochimie 2013;95:455-460.
28. He XS, Nanda S, Ji X, Calderon-Rodriguez GM, Greenberg HB, Liang TJ. Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes. J Interferon Cytokine Res 2010;30:311-320.
29. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006;131:1887-1898.
30. Holmes RS, Vandeberg JL, Cox LA. Genomics and proteomics of vertebrate cholesterol ester lipase (LIPA) and cholesterol 25-hydroxylase (CH25H). 3 Biotech 2011;1:99-109.
31. Anggakusuma, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, et al. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 2014;63:1137-1149.
32. Dawson PA, Van der Westhuyzen DR, Goldstein JL, Brown MS. Purification of oxysterol binding protein from hamster liver cytosol. J Biol Chem 1989;264:9046-9052.
33. Wang PY, Weng J, Anderson RG. OSBP is a cholesterol-regulated scaffolding protein in control of ERK 1/2 activation. Science 2005;307:1472-1476.
34. Reiss S, Harak C, Romero-Brey I, Radujkovic D, Klein R, Ruggieri A, et al. The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A. PLoS Pathog 2013;9:e1003359.
35. Romero-Brey I, Merz A, Chiramel A, Lee JY, Chlanda P, Haselman U, et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog 2012;8:e1003056.
36. Paul D, Madan V, Bartenschlager R. Hepatitis C virus RNA replication and assembly: living on the fat of the land. Cell Host Microbe 2014;16:569-579.
37. Ikegami T, Honda A, Miyazaki T, Kohjima M, Nakamuta M, Matsuzaki Y. Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. Biochem Biophys Res Commun 2014;446:736-740.
38. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003;72:137-174.
39. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol 2014;61:S14-S25.
40. Chen Y, Wang S, Yi Z, Tian H, Aliyari R, Li Y, et al. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Sci Rep 2014;4:7242.
41. Xiang Y, Tang JJ, Tao W, Cao X, Song BL, Zhong J. Identification of cholesterol-25-hydroxylase as a novel host restriction factor as a part of primary innate immune responses against hepatitis C virus infection. J Virol 2015;89:6805-6816.
42. Cyster JG, Dang EV, Reboldi A, Yi T. 25-Hydroxycholesterols in innate and adaptive immunity. Nat Rev Immunol 2014;14:731-743.
43. Gold ES, Diercks AH, Podolsky I, Podyminogin RL, Askovich PS, Treuting PM, et al. 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling. Proc Natl Acad Sci USA 2014;111:10666-10671.
44. Owen DM, Huang H, Ye J, Gale M Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009;394:99-108.
45. Pezacki JP, Sagan SM, Tonary AM, Rouleau Y, Belanger S, Supekova L, et al. Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus. BMC Chem Biol 2009;9:2.
46. Staeheli P, Pitossi F, Pavlovic J. Mx proteins: GTPases with antiviral activity. Trends Cell Biol 1993;3:268-272.
47. Pavlovic J, Staeheli P. The antiviral potentials of Mx proteins. J Interferon Res 1991;11:215-219.
48. Nagy PD, Pogany J. The dependence of viral RNA replication on co-opted host factors. Nat Rev Microbiol 2011;10:137-149.
49. Wang H, Perry JW, Lauring AS, Neddermann P, De Francesco R, Tai AW. Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking. Gastroenterology 2014;146:1373-1385.
50. Khan I, Katikaneni DS, Han Q, Sanchez-Felipe L, Hanada K, Ambrose RL, et al. Modulation of hepatitis C virus genome replication by glycosphingolipids and four-phosphate adaptor protein 2. J Virol 2014;88:12276-12295.
51. Paul D, Hoppe S, Saher G, Krijnse-Locker J, Bartenschlager R. Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. J Virol 2013;87:10612-10627.
52. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011;9:32-45.
53. Strating JR, van der Linden L, Albulescu L, Bigay J, Arita M, Delang L, et al. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep 2015;10:600-615.
54. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol 2013;87:4252-4260.
55. Chatel-Chaix L, Bartenschlager R. Dengue virus- and hepatitis C virus-induced replication and assembly compartments: the enemy inside-caught in the web. J Virol 2014;88:5907-5911.
56. Rothwell C, Lebreton A, Young Ng C, Lim JY, Liu W, Vasudevan S, et al. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 2009;389:8-19.